CA-LIVERAMP
15.6.2021 15:32:12 CEST | Business Wire | Press release
LiveRamp ® (NYSE: RAMP) today announced an expanded global partnership with Carrefour (OTCMKTS: CRERF) to enable robust data collaboration, analytics and innovation capabilities through LiveRamp’s Safe Haven . Using LiveRamp’s best-in-class privacy-preserving technologies, retailers, consumer packaged goods (CPGs) brands and Carrefour partners can execute safe, simple and productive data collaboration on an unprecedented global scale. Safe Haven is currently available in the U.S., UK, France, China, Japan and Australia, and, with Carrefour, is expanding to Spain, Italy, Belgium, Poland, Romania, Argentina, Brazil and Taiwan. LiveRamp’s Safe Haven is part of a new business unit that Carrefour is launching on this occasion: “Carrefour Links .” The partnership was announced at a press conference in Paris today.
“LiveRamp will be a critical accelerator of Carrefour’s transformation into an industry-leading data-driven retailer,” said Elodie Perthuisot, Executive Director E-Commerce, Data and Digital Transformation Carrefour Group. “We are delivering great value by working more collaboratively with our CPG and retail supply partners with Carrefour Links. We are excited by our partnership with LiveRamp, working together to deliver robust new consumer insights and capabilities to hundreds of our CPG partners on a global scale.”
By delivering data connectivity and identity management in a neutral, secure and permissioned environment, LiveRamp makes a breadth of new use cases and revenue streams possible for retailers while transforming the way they work with their supply partners. Through Carrefour Links, Safe Haven enables Carrefour to partner more closely with its CPG partners across nine international markets to deliver enhanced data collaboration capabilities including:
- Deeper Insights and Analytics 一Packaged reports provide robust insights into campaign performance, category management, and shopper analytics. Safe Haven also offers the ability for data science teams to utilize their own models and machine learning.
- Omnichannel Activation 一Activate CPG campaigns using Carrefour data across social and open web platforms and Carrefour owned-and-operated assets.
- Better Measurement 一CPGs can better understand the impact of marketing activities on sales utilizing retail data and move the needle to drive key business outcomes.
“Data is transforming the customer experience globally – and Carrefour is at the very forefront of this trend with its Carrefour Links platform,” said Warren Jenson, president of LiveRamp. “With LiveRamp Safe Haven, brands and their partners can now safely collaborate to deliver better customer experiences and drive business outcomes. We are proud to enable this groundbreaking capability for Carrefour across its CPG partner network and in over nine countries.”
LiveRamp’s expanded partnership with Carrefour signals the growing momentum of Safe Haven, which now serves more than 45 customers across retail, grocery, CPG, consumer electronics and other verticals. LiveRamp’s recent acquisition of DataFleets brings industry-leading privacy-enhancing technologies to Safe Haven, allowing customers to implement configurable data controls. LiveRamp’s Safe Haven makes data collaboration safe and easy for customers regardless of the technical infrastructure or cloud platform used by each party, without moving data.
“Safe Haven is enabling clients to collaborate across clouds, partners and borders to drive innovation, deliver better customer experiences and achieve competitive advantage,” continued Jenson. “In just over a year since announcing Safe Haven, we’ve gained 30% market share within U.S. grocery and big box retail, and in Europe are trailblazing the way with Carrefour and other leading retailers. As we continue to expand our international footprint, we are excited to now serve more than 30% of the 50 largest global CPGs.”
Visit the LiveRamp website to find more information on Safe Haven and Safe Haven for Retail .
About Carrefour Group
With a multi-format network of some 13 000 stores in more than 30 countries, the Carrefour Group is one of the world's leading food retailers. Carrefour recorded gross sales of €78.6 billion in 2020. It has more than 320,000 employees who help to make Carrefour the world leader in the food transition for everyone, providing everybody with access to high-quality, affordable food every day, in all locations.
For more information, visit www.carrefour.com , or find us on Twitter (@GroupeCarrefour) and LinkedIn (Carrefour).
About LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom